Abstract
Neuroautoimmune disorders, such as multiple sclerosis and Guillain-Barre syndrome, have been documented in relation to various vaccines in the past. This paper uses passive reporting information from the CDC/FDA’s VAERS system to analyse whether neuroautoimmune presentations are reported at a relatively higher or lower rate, vis-a-vis other adverse effects, for COVID-19 vaccines than for other vaccines. Through computing the reporting odds ratios for a range of symptoms and comparator vaccines, a clear indication in favour of the safety of COVID-19 vaccines emerges, with reports of neuroautoimmune adverse events in relation to other adverse events being over 70% less likely for COVID-19 than for comparator vaccines (ROR : 0.292, p < 0.0001). In comparison with other vaccines given as part of routine care in adulthood, COVID-19 vaccines have the lowest reporting odds ratio of neuroautoimmune adverse effects (median ROR: 0.246).
Competing Interest Statement
CvC is a consultant to a company that may be affected by the research reported in this paper. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Funding Statement
This research was funded by Starschema Inc. under its intramural research funding programme.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approval has been sought as the study involves publicly available data released by the CDC/FDA.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contingency tables were reformatted to present the contingency case counts and Pearson's residuals in a more readable manner.
Data Availability
Source data can be obtained from the FDA/CDC's VAERS site. All code is publicly available on Github and under the DOI 10.5281/zenodo.4940261.
https://vaers.hhs.gov/data.html
https://github.com/chrisvoncsefalvay/covid19-neuroautoimmune-aefis
Abbreviations
- AEFI
- Adverse event following immmunization
- CDC
- Centers for Disease Control and Prevention
- CIS
- clinically isolated syndrome
- EUA
- Emergency Use Authorization
- FDA
- Food and Drug Administration
- GBS
- Guillain-Barre syndrome
- mRNA
- messenger RNA
- MS
- multiple sclerosis
- QoL
- quality of life
- RIS
- radiologically isolated syndrome
- ROR
- Reporting Odds Ratio
- VAERS
- Vaccine Adverse Effect Reporting System
